ions.bio GmbH. (9/13/24). "Press Release: ions.bio Announces Development of Revolutionary All-in-One Biomarker Discovery Platform". Munich.

	Organisation	ions.bio GmbH
	Organisation 2	OmicEra Diagnostics GmbH
	Product	biomarker discovery technology
	Product 2	AI-based diagnostics
	Person	Geyer, Philipp E. (ions.bio 202408– Managing Director + Co-Founder before OmicEra Diagnostics)
	Person 2	Viellechner, Sophia (ions.bio 202409 CBO + Co-Founder)

ions.bio, a new biotech startup, today announced the launch of its comprehensive biomarker discovery and validation platform. The company offers an all-in-one solution that combines proprietary study design, clinical partnerships, multi-omics data generation, and advanced AI-driven analysis to uncover innovative biomarkers.

ions.bio's platform is designed to support biotech and pharmaceutical companies throughout the entire biomarker discovery process, from initial concept to final validation. By leveraging state-of-the-art technologies and a team of seasoned experts, the company aims to accelerate the development of novel diagnostic and therapeutic tools.

"Our mission is to revolutionize biomarker discovery by providing a seamless, integrated approach that combines scientific expertise with cutting-edge technology," said Philipp Geyer, managing director and co-founder of ions.bio. "We believe our platform will significantly accelerate the pace of biomarker research and ultimately lead to better patient outcomes."

The company was founded by the team behind OmicEra Diagnostics, bringing together a wealth of experience in proteomics, bioinformatics, and AI. The leadership includes:

> Philipp Geyer, managing director & CSO, an expert in plasma proteomics

> Sebastian Virreira Winter, managing director & CTO, heading the bioinformatics platform

> Sophia Viellechner, CBO, heading business development

> Prof. Jonathan Schmid-Burgk, Scientific Co-founder

ions.bio is now actively seeking partnerships with biotech and pharmaceutical companies to drive forward the next generation of biomarker discovery.

For more information, visit www.ions.bio.

About ions.bio

ions.bio is a biotech company dedicated to revolutionizing biomarker discovery through its comprehensive, AI-driven platform. By combining proprietary study design, clinical partnerships, a multi-omics data generation platform, and advanced analysis, ions.bio aims to accelerate the development of innovative biomarkers for improved diagnostics and therapeutics.

Record changed: 2024-09-18

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]